Data showing chemotherapy usage patterns in U.S. patients with metastatic colorectal cancer found 53% had received second-line treatments, 28% got third-line treatments and only a minority had access to all active agents. The study, which ran from 2004 to 2011 and included almost 4,900 patients, found 51% of patients were treated with the first-line therapy bevacizumab.

Related Summaries